country_code

What Is Federated Learning?

Federated learning is a way to develop and validate AI models from diverse data sources while mitigating the risk of compromising data security or privacy, as the data never leaves individual sites.
by
AI healthcare

Editor’s note: On April 16, 2024, we updated our original post on federated learning, which was first published October 13, 2019. 

The key to becoming a medical specialist, in any discipline, is experience.

Knowing how to interpret symptoms, which move to make next in critical situations, and which treatment to provide — it all comes down to the training you’ve had and the opportunities you’ve had to apply it.

For AI algorithms, experience comes in the form of large, varied, high-quality datasets. But such datasets have traditionally proved hard to come by, especially in the area of healthcare.

Federated learning is a way to develop and validate accurate, generalizable AI models from diverse data sources while mitigating the risk of compromising data security or privacy. It enables AI models to be built with a consortium of data providers without the data ever leaving individual sites.

Medical institutions have had to rely on their own data sources, which can be biased by, for example, patient demographics, the instruments used or clinical specializations. Or they’ve needed to pool data from other institutions to gather all of the information they need, which requires managing regulatory issues.

Federated learning makes it possible for AI algorithms to gain experience from a vast range of data located at different sites.

The approach enables several organizations to collaborate on the development of models, but without needing to directly share sensitive clinical data with each other.

Over the course of several training iterations the shared models get exposed to a significantly wider range of data than what any single organization possesses in-house.

Federated learning is gaining traction beyond healthcare, moving into financial services, cybersecurity, transportation, high performance computing, energy, drug discovery and other fields.

Frameworks such as NVIDIA FLARE (NVFlare) have enabled enterprises to collaborate by contributing data through federated learning for model improvements.

NVFlare, an open-source federated learning framework that’s widely adopted across various applications, offers a diverse range of examples of machine learning and deep learning algorithms. It includes robust security features, advanced privacy protection techniques and a flexible system architecture — building trust among users.

How Federated Learning Works 

The main concept of federated learning is to train models locally without sharing data, only the model parameters.

The aggregator starts with an initial global model and broadcasts the model parameters to all clients. The client node receives the global model parameters and starts training the received model on local data. Then, the newly trained local model is sent back to the aggregator node. Only model parameters, no private data, are shared with the aggregator.

The aggregator node will perform aggregation, such as weighted average, to produce a new global model. That new global model will be broadcast again by repeating the first step until convergence, or until it’s reached the max number of rounds.

AI algorithms deployed in medical scenarios ultimately need to reach clinical-grade accuracy. Largely speaking, this means that they meet, or exceed, the gold standard for the application to which they’re applied.

To be considered an expert in a particular medical field, you generally need to have clocked 15 years on the job. Such an expert has probably read around 15,000 cases in a year, which adds up to around 225,000 over their career.

When you consider rare diseases, which affect around one in 2,000 people, even an expert with three decades’ experience will have only seen roughly 100 cases of a particular condition.

To train models that meet the same grade as medical experts, the AI algorithms need to be fed a large number of cases. And these examples need to sufficiently represent the clinical environment in which they’ll be used.

But currently the largest open dataset contains 100,000 cases.

And it’s not only the amount of data that counts. It also needs to be very diverse and incorporate samples from patients of different genders, ages, demographics and environmental exposures.

Individual healthcare institutes may have archives containing hundreds of thousands of records and images, but these data sources are typically kept siloed. This is largely because health data is private and cannot be used without the necessary patient consent and ethical approval.

Federated learning decentralizes deep learning by removing the need to pool data into a single location. Instead, the model is trained in multiple iterations at different sites.

For example, say three hospitals decide to team up and build a model to help automatically analyze brain tumor images.

If they chose to work with a client-server federated approach, a centralized server would maintain the global deep neural network and each participating hospital would be given a copy to train on their own dataset.

Once the model had been trained locally for a couple of iterations, the participants would send their updated version of the model back to the centralized server and keep their dataset within their own secure infrastructure.

The central server would then aggregate the contributions from all of the participants. The updated parameters would then be shared with the participating institutes, so that they could continue local training.

A centralized-server approach to federated learning.

If one of the hospitals decided it wanted to leave the training team, this would not halt the training of the model, as it’s not reliant on any specific data. Similarly, a new hospital could choose to join the initiative at any time.

This is just one of many approaches to federated learning. The common thread through all approaches is that every participant gains global knowledge from local data — everybody wins.

Why Federated Learning?

Federated learning still requires careful implementation to ensure that patient data is kept secure. But it has the potential to tackle some of the challenges faced by approaches that require the pooling of sensitive clinical data.

For federated learning, clinical data doesn’t need to be taken outside an institution’s own security measures. Every participant keeps control of its own clinical data.

As this makes it harder to extract sensitive patient information, federated learning opens up the possibility for teams to build larger, more diverse datasets for training their AI algorithms.

Implementing a federated learning approach also encourages different hospitals, healthcare institutions and research centers to collaborate on building a model that could benefit them all.

How Federated Learning Can Transform Industries

Federated learning could revolutionize how AI models are trained, with the benefits also filtering out into the wider healthcare ecosystem.

Larger hospital networks would be able to work better together and benefit from access to secure, cross-institutional data. While smaller community and rural hospitals would enjoy access to expert-level AI algorithms.

It could bring AI to the point of care, enabling large volumes of diverse data from across different organizations to be included in model development, while complying with local governance of the clinical data.

Clinicians would have access to more robust AI algorithms, based on data that represents a wider demographic of patients for a particular clinical area or from rare cases that they would not have come across locally. They’d also be able to contribute back to the continued training of these algorithms whenever they disagreed with the outputs.

Healthcare startups could bring cutting-edge innovations to market faster, thanks to a secure approach to learning from more diverse algorithms.

Meanwhile, research institutions would be able to direct their work toward actual clinical needs, based on a wide variety of real-world data, rather than the limited supply of open datasets.

Large-scale federated learning projects are now starting, hoping to improve drug discovery and bring AI benefits to the point of care.

MELLODDY, a drug-discovery consortium based in the U.K., aims to demonstrate how federated learning techniques could give pharmaceutical partners the best of both worlds: the ability to leverage the world’s largest collaborative drug compound dataset for AI training without sacrificing data privacy.

King’s College London is hoping that its work with federated learning, as part of its London Medical Imaging and Artificial Intelligence Centre for Value-Based Healthcare project, could lead to breakthroughs in classifying stroke and neurological impairments, determining the underlying causes of cancers, and recommending the best treatment for patients.

In the context of financial services, federated learning can be applied to train a model using data from several banks to estimate individual transaction risk scores while keeping personal information locally at the banks.

Fraud detection is an important federated learning use case for banking and insurance. Institutions can harness data from user accounts and fraud cases to create better fraud-detection models without sacrificing user data privacy.

This can be challenging without federated learning, considering data privacy protection laws such as the EU’s GRPR, China’s PIPL and the recent EU AI Act, which prohibits cross-border data sharing. With federated learning, financial institutions can comply with these laws and regulations while using rich, private datasets for better, safer outcomes.

NVFlare can be used with XGBoost and Kaggle’s Credit Card Fraud Detection dataset for securing credit card transactions and with graph neural networks (GNNs) for financial transaction classification.

Federated learning is also applicable in use cases such as federated data analytics on edge medical devices, cross-board data training with autonomous vehicle models and drug discovery. Driven by data privacy regulations, the need to build better models with more private data, as well as the generative AI boom, the adoption of federal learning is accelerating.

Learn more about NVFlare. Explore more about federated learning on related NVIDIA technical blogs. And discover the science behind the approach, in this paper.

 

From Scan to Treatment Plan, AI Helps Close Breast Cancer’s Deadliest Gaps

NVIDIA Inception companies are applying AI to each stage of the breast cancer care journey — imaging, risk assessment and treatment decisions.
by

Breast cancer is the most commonly diagnosed cancer among American women — yet the gaps in care are wide. A majority of women over age 40 skip the recommended annual screening. Radiologists are reading more mammograms with fewer colleagues. And when a diagnosis arrives, the tests that inform treatment can take weeks to return results. 

Companies in the NVIDIA Inception program for startups are building AI applications to support clinicians at each of these friction points, including imaging, risk assessment and treatment planning.

About 40 million mammograms are performed in the U.S. each year, but a projected shortfall of tens of thousands of radiologists over the next decade is straining the system’s capacity to read them. 

At the other end of the care timeline, treatment decisions often hinge on genomic assays sent off to outside labs — assays that take weeks to process, at a moment when speed and certainty matter most. 

The companies below are addressing both ends of that gap, and everything in between, accelerated by NVIDIA AI infrastructure.

Automated Imaging Delivers AI-Powered Insights

For women struggling to find time or a nearby location for breast cancer screening, access is a practical barrier that translates into missed diagnoses. NVIDIA Inception startup iSono Health was built around simplifying this imaging workflow.

The company’s FDA-cleared ATUSA platform — a wearable, automated 3D quantitative ultrasound system — captures a standardized breast volume in approximately two minutes per breast, compared with up to 45 minutes for a conventional handheld ultrasound. 

The system’s AI, trained on thousands of full-breast scans comprising over 1.5 million ultrasound frames, automates image acquisition. It uses NVIDIA GPU acceleration and open source medical imaging technology to deliver a 3D scan that the company says is 28% more sensitive than a handheld 2D ultrasound.

 

Handheld ultrasound depends on whoever holds the probe, so a woman’s scans typically can’t be compared from one year to the next. ATUSA captures the whole breast the same way every time, creating a repeatable view of breast tissue that could help clinicians analyze how a patient’s tissue changes across successive scans, while also reducing operator errors and variability.

ATUSA is commercially available through partner clinics across California, Texas, Georgia, Tennessee and Washington D.C., with new sites coming online regularly. 

“Getting the scan closer to the patient is the first breakthrough,” said Neda Razavi, CEO of iSono Health. “Our vision is to make that scan increasingly informative: helping clinicians see what is there, understand what has changed and make more informed decisions.” 

iSono Health has developed AI capabilities for lesion detection, 3D segmentation and lesion classification. It next plans to extend its AI pipeline into multimodal diagnostic intelligence spanning 3D ultrasound, mammography, MRI and clinical information.

The company has a multicenter clinical study with 3,200 patients underway to further validate the platform’s performance, with lead research sites at UC Davis and Vanderbilt University Medical Center. 

Finding Cancers, Cutting False Alarms

Another NVIDIA Inception company, Whiterabbit.ai, develops AI technology for breast cancer screening. Its FDA-cleared WRDensity software automatically assesses breast density from mammograms and has been used in the care of hundreds of thousands of patients.

The company has also developed WRRisk, a clinical decision support software for estimating patients’ long-term risk of developing breast cancer — and is researching a new generation of AI for mammography that could help radiologists detect more cancers while automating the screening of mammograms that are negative for breast cancer. 

The goal is to reduce the burden on a strained radiologist workforce, accelerate results and reduce avoidable callbacks for patients, and lower downstream healthcare costs.

Whiterabbit.ai’s FDA-cleared WRDensity software automatically assesses breast density from mammograms.

“Every day, breast radiologists face a needle-in-a-haystack problem, trying to find roughly one cancer in every 200 mammograms,” said Jason Su, cofounder and chief technology officer of Whiterabbit.ai. “We hope AI can be a powerful sidekick to radiologists, helping to clear away the hay so they can focus their expertise where it matters most.”

Whiterabbit trains its AI models on a cluster of NVIDIA GPUs housed at Washington University in St. Louis, supplemented by additional GPU capacity in the cloud. Inference runs on NVIDIA GPUs deployed directly in the clinic.

Predicting Which Treatments Will Work

Once a patient is diagnosed with breast cancer, the next question is what to do about it — and the answer depends on predicting how the cancer will respond to treatment. 

Today, these predictions are limited in scope and accuracy, and often require a separate tissue biopsy with a two- to four-week wait. Ataraxis AI is building clinical intelligence that predicts patient outcomes and response to different therapies using digital data, including pathology slides that are already part of the standard patient workup.

Ataraxis’ AI models interpret patterns in pathology slides, visualized here as color-coded clusters. The models learn to associate variations among these patterns with differences in recurrence risk and chemosensitivity.

“The tools oncologists rely on today to guide therapy decisions were largely trained once, fifteen years ago, and never updated. Our models get stronger every time we acquire more clinical trial data,” said Joseph Cappadona, member of technical staff at Ataraxis AI. “But as we scale our models, the bigger shift is being able to answer more questions to help oncologists personalize therapy across all cancers.”

Ataraxis’s AI models analyze digital pathology slides and standard clinical variables to predict treatment response and recurrence risk. One model predicts whether presurgical chemotherapy is likely to shrink a patient’s tumor to the point of response before the operating room. After surgery, another model estimates a patient’s five-year recurrence risk and the likely benefit of chemotherapy as a next step. 

Both models have been validated across more than 10 institutions and multiple clinical trials, and are in active clinical use. They run on NVIDIA GPUs on premises, in an offsite data center and in the cloud — using PyTorch accelerated by NVIDIA CUDA throughout.

Providing Tumor Insights With 3D Visualization

Another NVIDIA Inception company, SimBioSys, joined NVIDIA on a recent panel marking Breast Cancer Awareness Month. 

The company builds AI-powered precision medicine technology that creates accurate 3D models of breast tumors, veins and other soft tissue, delivering important insights to help guide surgeries and influence treatment plans. It has also built a tool to estimate the risk of breast cancer recurrence based on 3D volumetric data from a patient’s breast MRI, tumor pathology and clinical data. 

“We’re building a platform that now allows us to take multimodal data — imaging exams, pathology results, genomic testing when applicable and other biological inputs — and, using AI, bring that all together,” said Stacey Stevens, CEO of SimBioSys, at the event. “When we do that, it generates new insights beyond what we had from any individual piece.”

Stacey Stevens, CEO of SimBioSys, and Chelsea Sumner, healthcare AI startups lead for North and Latin America at NVIDIA, spoke on an October 1 panel in Phoenix, Arizona, on AI’s role in advancing breast cancer care.

SimBioSys uses NVIDIA MONAI for training and validation data, and NVIDIA CUDA-X libraries including cuBLAS and MONAI Deploy for its imaging technology, which runs on NVIDIA GPUs in the cloud. 

“NVIDIA technology gives us the computing power to take hundreds or thousands of images, apply our AI and analyze them quickly,” Stevens said. “That speed matters because patients and physicians need answers quickly. They can’t afford to wait days or weeks.”

Learn more about the NVIDIA Inception program for startups.

Certain technologies described in this article are investigational and have not been approved by the U.S. FDA for commercial use.

  • Categories:
  • AI

How NVIDIA GPUs Help Accelerate OpenAI’s GPT-6 Astra Ultrafast

Running on NVIDIA Blackwell GPUs and accelerated by continuous inference optimizations through OpenAI’s models, GPT-6 Astra Ultrafast delivers faster model responses across code generation, tool use and interactive applications.
by

GPT-6 Astra Ultrafast, running on NVIDIA Blackwell GPUs, is available now in the OpenAI API and to eligible ChatGPT Work and Codex users. 

Accelerated by inference optimizations through OpenAI’s models that tap into the capabilities of the NVIDIA Blackwell architecture, Ultrafast offers up to 8x faster token generation than the Astra Standard mode. For developers, faster generation can shorten coding agents’ edit-test-debug cycles, reduce the time spent generating responses between tool calls and make interactive applications feel more responsive. 

A faster response matters most when it’s repeated across a workflow: an agent writes code, uses a tool, checks the result and decides what to do next. Ultrafast brings Astra’s capabilities into these time-sensitive loops. NVIDIA AI infrastructure helps OpenAI serve more useful model outputs when developers need it. 

“NVIDIA’s deep investment in tooling and documentation has enabled us to make our models exceptionally good at programming Blackwell and Rubin GPUs,” said Philippe Tillet, inference lead at OpenAI. “Astra can turn that knowledge into high-performance kernels that make NVIDIA hardware compelling across the full frontier of latency, throughput and cost. With Astra Ultrafast, that means faster model responses as agents write code, use tools and work through complex tasks.”

Continually Improving Performance

Performance gains don’t stop when a model is deployed. OpenAI is using its own models to help refine the inference software running on NVIDIA GPUs, taking advantage of the platform’s programmability to test and implement improvements. That ongoing work can make model responses faster and deployed infrastructure more productive over time. 

“Our work with NVIDIA is helping us make AI faster and more useful,” said Uday Ruddarraju, chief technology officer of compute at OpenAI. “We used our internal models to optimize inference on NVIDIA GPUs, and NVIDIA’s programmability helped us deliver the acceleration behind Astra Ultrafast.”

A programmable NVIDIA platform allows developers and researchers to reuse infrastructure across training, inference and reinforcement learning as models evolve. That flexibility helps teams repurpose compute resources as demand changes, improving utilization and avoiding overprovision for each workload.

Developers can use GPT-6 Astra Ultrafast through the API today. See the Ultrafast guide for access, pricing and implementation details.

NVIDIA Opens Applications for 2027–2028 Graduate Fellowships With Awards Up to $60,000

by

Bringing together the world’s brightest minds and the latest accelerated computing technology leads to powerful breakthroughs that help tackle some of the biggest research problems.

To foster such innovation, the NVIDIA Graduate Fellowship Program provides grants, mentors and technical support to doctoral students doing outstanding research relevant to NVIDIA technologies. The program, in its 26th year, is now accepting applications worldwide.

It focuses on supporting students working in AI, machine learning, autonomous vehicles, computer graphics, robotics, healthcare, high-performance computing and related fields. Awards are up to $60,000 per student.

Since its start in 2002, the Graduate Fellowship Program has awarded over 220 grants worth around $8 million.

Students must have completed at least their first year of Ph.D.-level studies at the time of application.

The application deadline for the 2027-2028 academic year is October 30, 2026. An in-person internship at an NVIDIA research office preceding the fellowship year is mandatory; eligible candidates must be available for the internship in summer 2027.

For more on eligibility and how to apply, visit the program website.

Featured image shows last year’s NVIDIA Graduate Fellowship recipients.